NSE · VINEETLAB
Vineet Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹77 Cr with net profit ₹-20 Cr — a -26.23% net margin, versus 0.68% the period before.
Shareholding
As of 2026-09-30
- Promoter5.98%
- Public93.78%
- FII0.24%
9,724 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.56× from low to high.
Risk flags
Derived from disclosed data
- Reported zero revenue in 2 of the last 7 disclosed periods.
Peer comparison
Chemicals · ranked #122 of 161 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Solar Industries India Ltd. | ₹1,68,384 Cr | 74.39 | 21.93 | 29.5% | 17.7% |
| Pidilite Industries Ltd. | ₹1,60,827 Cr | 59.92 | 14.32 | 23.94% | 16.63% |
| SRF Ltd. | ₹72,932 Cr | 30.88 | 4.81 | 14.92% | 12.76% |
| Linde India Limited | ₹58,496 Cr | 118.36 | 13.32 | 11.26% | 18.08% |
| Gujarat Fluorochemicals Ltd. | ₹51,251 Cr | 75.18 | 6.1 | 7.97% | 11.43% |
| Navin Fluorine International Ltd. | ₹46,234 Cr | 50.46 | 10.36 | 20.41% | 22.4% |
| Godrej Industries Ltd. | ₹32,198 Cr | 26.32 | 2.88 | 11.1% | 5.06% |
| Himadri Speciality Chem Limited | ₹28,667 Cr | 33.54 | 5.59 | 16.65% | 15.28% |
| Deepak Nitrite Ltd. | ₹20,917 Cr | 19.53 | 3.23 | 16.4% | 10.9% |
| Aether Industries Limited | ₹20,731 Cr | 82.24 | 7.99 | 9.61% | 19.21% |
| Vineet Laboratories Ltd.(this company) | ₹71 Cr | 20.35 | 1.56 | 2.44% | 5.6% |
AI analysis
AI-generated · google/gemini-2.5-flashVineet Laboratories Ltd. has a market capitalization of Rs 72 Cr. The company reported revenue of Rs 76.98 Cr in the latest fiscal year. Its book value is Rs 15.89. The company's EPS is -21.9 and it has a negative ROCE of -22.411%.
Positives
- +The promoter pledge is 0%, indicating no shares are pledged.
- +FII holding has a presence at 0.36% as of March 2026.
Negatives
- −The company reported a negative EPS of -21.9 in Mar 2025.
- −Revenue has significantly declined to Rs 76.98 Cr in Mar 2025 from Rs 243.86 Cr in Mar 2021.
- −The company reported a net loss of Rs -20.19 Cr in Mar 2025.
- −Return on Capital Employed (ROCE) is negative at -22.411%.
- −Promoter holding has decreased substantially from 38.66% in Mar 2023 to 5.98% in Mar 2026.
- −The debt-to-equity ratio is high at 1.71.
Financial performance
Vineet Laboratories Ltd. has experienced a decline in revenue over recent years. Revenue decreased from Rs 243.86 Cr in Mar 2021 to Rs 76.98 Cr in Mar 2025. Net profit also saw a significant drop, falling from Rs 1.78 Cr in Mar 2021 to a net loss of Rs -20.19 Cr in Mar 2025. The company's latest annual EBITDA was -16.79 Cr in Mar 2025.
Profitability & returns
The company's profitability has deteriorated, with a negative EPS of -21.9 in Mar 2025, down from 1.11 in Mar 2024. Return on Capital Employed (ROCE) is significantly negative at -22.411%. Return on Equity (ROE) is 0%, reflecting no returns for equity shareholders. The net profit has moved from positive to negative, reporting a loss of Rs -20.19 Cr in Mar 2025.
Balance sheet
Vineet Laboratories Ltd. has a debt-to-equity ratio of 1.71, indicating a reliance on debt financing. The book value per share is Rs 15.89. The company's EBITDA for Mar 2025 was -16.79 Cr, while its net profit was -20.19 Cr in the same period.
Ownership & pledges
Public shareholding is dominant at 93.66%. There are no shares pledged by the promoters.
Data as of — price: 2026-11-07 · financials: Mar 25 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.